These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23234615)

  • 1. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
    Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
    Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
    Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
    Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
    Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
    J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.
    Matsukawa Y; Hattori R; Sassa N; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2013 Mar; 32(3):266-70. PubMed ID: 22907775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
    Kessler TM; Studer UE; Burkhard FC
    J Urol; 2006 Oct; 176(4 Pt 1):1487-92. PubMed ID: 16952666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of maximum detrusor contraction power in relation to bladder emptying in patients with lower urinary tract symptoms and benign prostatic enlargement.
    Rosier PF; de Wildt MJ; de la Rosette JJ; Debruyne FM; Wijkstra H
    J Urol; 1995 Dec; 154(6):2137-42. PubMed ID: 7500477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha1-Adrenergic blockers in young men with primary bladder neck obstruction.
    Yang SS; Wang CC; Hsieh CH; Chen YT
    J Urol; 2002 Aug; 168(2):571-4. PubMed ID: 12131312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.